The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 3

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3 · randomised · 400 people · 366 sites in 25 countries · Recruiting now

August 7, 2026
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Phase 3 · randomised · 364 people · 187 sites in 2 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now

August 7, 2026
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 · randomised · 700 people · 254 sites in 21 countries · Recruiting now

August 7, 2026
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Phase 3 · randomised · 600 people · 166 sites in 12 countries · Recruiting now

August 7, 2026
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 3 · randomised · 990 people · 281 sites in 26 countries · Recruiting now

August 7, 2026
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Phase 3 · randomised · 1,912 people · 1,066 sites in 3 countries · Recruiting now

August 7, 2026
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer

Phase 3 · randomised · 477 people · 223 sites in 29 countries · Recruiting now

August 7, 2026